The study entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides a comprehensive insight into the US biosimilar market
Implementation of a smart card project requires a significant investment in setting up and upgradation of the current infrastructure. The cost of implementing a smart card based system is very high compared to the cost of smart cards
Driven by factors such as increasing popularity in preliminary testing, portability and ease of use; the market for Immunodiagnostics is expected to grow robustly in the coming years.
A number of smart card projects such as the UID, E-passports, EPFO, etc have been delayed or cancelled due to problems like lack of funds, technical issues, legal wrangling, etc.
A new report from IMARC Group finds that the Indian market for both diagnostic and therapeutic antibodies is expected to grow exponentially in the coming years.
The volume penetration of biosimilars in the US will strongly depend upon the complexity of the molecule, the patient pool that it caters and the extent of savings it brings to payers and providers
Hybrid vehicles largely depend upon four rare earth elements - Praseodymium, Neodymium, Terbium, and Dysprosium. Out of these four elements, the later three are expected to face a critical supply crunch in the near future.
The performance of HGH biosimilars cannot be taken as an analogue to project the uptake of other biosimilar classes as penetration rates of biosimilars in different biological classes are expected to be different from one another.
Excluding Mabthera, Roche's other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.
Despite a sluggish economic scenario, the expansion of new wind energy projects has so far continued unabated. A supply shortage of key raw materials, however, may jeopardize the growth of the entire industry.
India has historically lagged behind the west and other major Asian countries in the usage of smart cards. The country, however, is poised to enter a smart revolution or to make it more precise - a smart card revolution.
Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
With demand expected to significantly outpace supply in the coming years, India may not have enough milk to feed its own population - let alone feed others.
With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers.
Despite a recent bust, prospects for rare earth stocks will remain strong in the long term. Investors, however, will have to closely analyze the grade and composition of individual rare earths before investing in a mine.
Although it's clear that the market for cold chain healthcare products are poised for robust growth, a strong and reliable cold chain logistics infrastructure will be critical for the sector's development.
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint.
With the domestic demand of dairy products projected to outstrip supply, the presence of foreign dairy players in India is expected to increase in the coming years.
A new report from IMARC Group suggests that an increased research and development into technologies that nullify the need of cold chains could restrain the growth of the global cold chain logistics industry.
Despite worldwide efforts to reduce the consumption of rare earth elements, IMARC Group expects strategies like substitution and recycling to have a little effect on their demand and dependability in the short term.
A new report from IMARC Group expects a strong uptake of DPP-IV Inhibitors and other new drug classes to drive sales in the Turkish Oral Antidiabetics market during 2011-2016.
A new report from IMARC Group expects several factors such as value addition, increasing penetration in the cold beverage segment and rising institutional sales to drive the Indian tea market to sales worth US$ 7.2 Billion by 2016.
Healthcare manufacturers today are becoming more and more receptive to the notion that rather than risking the wastage of such high value products, it is more preferable to pay the extra cash to strengthen their distribution systems.
A new report from IMARC Group expects the strong growth of biopharmaceuticals and the launch of biosimilars to create huge opportunities for cold chain service providers.
A new study from IMARC Group suggests that it will take around 4 to 5 years for the country's skimmed milk powder production to reach levels that it had in 2008-09.
Driven by an increasing prevalence of diabetes, the total market for Insulin and Non-Insulin Antidiabetics is expected to reach sales worth US$ 2803 Million by 2015.
With outsourcing trends in the global clinical trials market increasing rapidly, the demand of efficient cold chain logistic services is predicted to grow robustly in the coming years.
A new report from IMARC Group expects that as a result of an avalanche of patent expiries and a thin pipeline, sales worth US$ 8.7 Billion will be eroded from the US cholesterol market.
A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
Driven by a strong growth in the sales of vaccines, the demand for efficient cold chain packaging and transportation services is expected to grow robustly in the coming years.
Driven by a high shelf life and an increased convenience, the demand for UHT milk in India is expected to grow more than three folds during 2010-11 and 2016-17.
A new report from IMARC Group expects an exponential growth in the demand of rare earth based magnets in the coming years. A supply shortage of key raw materials, however, may jeopardize the growth of this entire industry.
Driven by a strong growth in the sales of temperature sensitive healthcare products, IMARC Group expects the global healthcare cold chain logistics market to grow robustly in the coming years.
From less than 3% in 2010, Non-Chinese mines are expected to account for more than 37% of the global rare earth elements production by 2015, says a new report from IMARC Group.
Driven by a strong growth in the sales of temperature sensitive healthcare products, IMARC Group expects the global healthcare cold chain logistics market to reach values worth US$ 9.5 billion by 2016.
Driven by a rich pipeline and a strong safety-efficacy profile, the market for DPP-IV inhibitors in India is expected to reach more than US$ 163 Million in the next five years. This would represent around 17% of the total oral antidiabetics market by 2015.
A new report from IMARC Group expects that although the total supply of rare earth elements will exceed the total demand by more than 45,000 metric tons, we may face a global shortage of a number of critical rare earth elements.
IMARC Group, one of the world's leading research and advisory firms, finds that the sales of Biopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 to US$ 13.5 Billion in 2015.
IMARC Group, one of the world's leading research and advisory firms, finds that the sales of dairy products in India will nearly double its size from INR 2.6 Trillion (US$ 60 Billion) to around INR 5.1 Trillion (US$ 115 Billion) by 2016. IMARC's new report entitled "Indian Dairy Market Report & Forecasts 2011-2016" provides an analytical and statistical insight into the Indian Dairy market.
Driven by factors such as the worlds largest diabetes pool, rising affluence and an rapidiy improving medical infrastructure, the Indian diabetes market is expected to more than triple its value by 2015.
The prevalence of diabetes is growing at an alarming rate in China. Although, this represents a major challenge for the government and healthcare authorities, it is creating huge opportunities for pharmaceutical manufacturers.
Satisfied Users & 
Approved Press Releases
